Review
Avasimibe Pfizer
Affiliations
- PMID: 12498009
Item in Clipboard
Review
Avasimibe Pfizer
Curr Opin Investig Drugs.
2002 Sep.
Abstract
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
Similar articles
-
Pharmacology of the ACAT inhibitor avasimibe (CI-1011).Cardiovasc Drug Rev. 2003 Spring;21(1):33-50. Cardiovasc Drug Rev. 2003. PMID: 12595916 Review.
-
Avasimibe. CI 1011.Drugs R D. 2002;3(3):173-4. doi: 10.2165/00126839-200203030-00005. Drugs R D. 2002. PMID: 12099161 Review. No abstract available.
-
[Acyl-coenzyme A: cholesterol acyltransferase (ACAT)].Nihon Rinsho. 2004 Dec;62 Suppl 12:89-91. Nihon Rinsho. 2004. PMID: 15658270 Review. Japanese. No abstract available.
-
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.Pathophysiol Haemost Thromb. 2007;36(1):9-17. doi: 10.1159/000112634. Epub 2008 Mar 6. Pathophysiol Haemost Thromb. 2007. PMID: 18332609
-
Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):463-9. doi: 10.2174/156800605774962040. Curr Drug Targets Cardiovasc Haematol Disord. 2005. PMID: 16503866 Review.
Cited by
-
Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases.Pathogens. 2022 Mar 17;11(3):370. doi: 10.3390/pathogens11030370. Pathogens. 2022. PMID: 35335693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources